Brief: Biophytis Launches OBA Phase 2 Clinical Study In Obesity With Bio101 (20-Hydroxyecdysone)
08/04/2024 22:04
April 8 (Reuters) - Biophytis SA ALBPS.PA :
* BIOPHYTIS LAUNCHES OBA PHASE 2 CLINICAL STUDY IN OBESITY
WITH
BIO101 (20-HYDROXYECDYSONE)
* EXPECT FIRST RESULTS OF EFFICACY OF OUR DRUG CANDIDATE TO
BE
AVAILABLE IN 2025
* OBA PHASE 2 CLINICAL STUDY IS EXPECTED TO START MID 2024,
UPON
REGULATORY APPROVALS
* FIRST PATIENTS EXPECTED TO BE TREATED IN SECOND HALF OF
2024
Source text for Eikon: ID:nEQ6mFD6Ja
Further company coverage: ALBPS.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon